Phase 1 Trial Of Antifungal Drug (VL-2397) Targeting Invasive Aspergillosis

US drug company Vical said it has launched a Phase 1 clinical trial of its antifungal treatment, VL-2397. The randomized, double-blind trial will evaluate safety, tolerability and pharmacokinetics of VL-2397 at single and multiple ascending doses in healthy volunteers at a single U.S. clinical site. VL-2397 will be used to treat invasive aspergillosis, which causes significant morbidity and mortality in immunocompromised patients, including transplant recipients, the company said

Date of article/Start date of trial: 7 March 2016

Trial Phase: Phase 1

Back to New Antifungals